Phase 3
Completed N=606
A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia
Source: ClinicalTrials.gov NCT00855582 ↗Enrolled (actual)
606
Serious AEs
0.7%
Results posted
Jun 2011
Primary outcomePrimary: Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12 Endpoint (5 mg) — -6.1; -3.8 units on a scale — p=<0.001
Summary
Study LVHR is a Phase 3 study which will examine the efficacy and safety of tadalafil 2.5 and 5 mg once daily versus placebo for the treatment of erectile dysfunction (ED) and signs and symptoms of benign prostatic hyperplasia (BPH) in men with both ED and signs and symptoms of BPH.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12 Endpoint (5 mg) |
-6.1; -3.8 | <0.001 sig |
| PRIMARY Change From Baseline in International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score at Week 12 Endpoint (5 mg) |
6.5; 1.8 | <0.001 sig |
| PRIMARY Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12 Endpoint (2.5 mg) |
-4.6; -3.8 | 0.181 |
| PRIMARY Change From Baseline in International Index of Erectile Function - Erectile Function (IIEF-EF) Domain Score at Week 12 Endpoint (2.5 mg) |
5.2; 1.8 | <0.001 sig |
| SECONDARY Change From Baseline in Yes Responses to Sexual Encounter Profile (SEP) Diary Question 3 at Week 12 Endpoint (5 mg) |
31.7; 12.0 | <0.001 sig |
| SECONDARY Change From Baseline in Benign Prostatic Hyperplasia (BPH) Impact Index (BII) at Week 12 Endpoint (5 mg) |
-2.1; -1.2 | <0.001 sig |
| SECONDARY Change From Baseline in Yes Responses to Sexual Encounter Profile (SEP) Diary Question 3 at Week 12 Endpoint (2.5 mg) |
24.6; 12.0 | <0.001 sig |
| SECONDARY Change From Baseline in BPH Impact Index (BII) at Week 12 Endpoint (2.5 mg) |
-1.6; -1.2 | 0.156 |
| SECONDARY Change From Baseline in Modified IPSS (mIPSS) at Week 2 Endpoint |
-2.8; -4.0; -2.2 | 0.226 |
| SECONDARY Change From Baseline in International Prostate Symptom Score (IPSS) at Week 4 and Week 8 Endpoint |
-3.4; -5.5; -2.6; -4.5; -5.8; -3.8 | 0.121 |
| SECONDARY Change From Baseline in International Index of Erectile Function - Erectile Function (IIEF-EF) Domain at Week 4 and Week 8 Endpoint |
4.2; 6.1; 1.0; 4.9; 6.6; 1.8 | <0.001 sig |
| SECONDARY Change From Baseline in Yes Responses to Sexual Encounter Profile (SEP) Diary Question 3 at Week 4 and Week 8 Endpoint |
22.3; 30.7; 6.2; 22.9; 31.7; 10.9 | <0.001 sig |
| SECONDARY Change From Baseline in BPH Impact Index (BII) at Week 4 and 8 Endpoint |
-1.0; -1.5; -0.7; -1.4; -1.8; -1.2 | 0.215 |
| SECONDARY Change From Baseline in International Prostate Symptom Score Voiding (Obstructive) Subscore at Week 12 Endpoint |
-2.7; -3.6; -2.2 | 0.230 |
| SECONDARY Change From Baseline in International Prostate Symptom Score Storage (Irritative) Subscore at Week 12 Endpoint |
-1.9; -2.5; -1.6 | 0.191 |
| SECONDARY Change From Baseline in International Prostate Symptom Score Nocturia Question at Week 12 |
-0.5; -0.6; -0.5 | 0.763 |
| SECONDARY Change From Baseline in International Prostate Symptom Score Quality of Life (QoL) at Week 12 Endpoint |
-0.9; -1.0; -0.8 | 0.384 |
| SECONDARY Change From Baseline in International Index of Erectile Function - Overall Satisfaction Domain at Week 12 Endpoint |
1.8; 2.4; 0.5 | <0.001 sig |
| SECONDARY Change From Baseline in International Index of Erectile Function - Intercourse Satisfaction Domain at Week 12 Endpoint |
1.6; 2.0; 0.2 | <0.001 sig |
| SECONDARY Change From Baseline in International Index of Erectile Function Question 3 at Week 12 Endpoint |
0.9; 1.1; 0.2 | <0.001 sig |
| SECONDARY Change From Baseline in International Index of Erectile Function Question 4 at Week 12 Endpoint |
0.9; 1.3; 0.4 | <0.001 sig |
| SECONDARY Change From Baseline in Yes Responses to Sexual Encounter Profile (SEP) Diary Question 2 at Week 12 Endpoint |
21.4; 25.1; 9.3 | <0.001 sig |
| SECONDARY Change From Baseline in Yes Responses to Sexual Encounter Profile (SEP) Diary Question 4 at Week 12 Endpoint |
26.6; 39.4; 9.6 | <0.001 sig |
| SECONDARY Change From Baseline in Yes Responses to Sexual Encounter Profile (SEP) Diary Question 5 |
23.7; 38.2; 9.9 | <0.001 sig |
| SECONDARY Patient Global Impression of Improvement (PGI-I) at Week 12 Endpoint |
0; 0; 1; 3; 2; 4 | <0.001 sig |
| SECONDARY Clinician Global Impression of Improvement (CGI-I) at Week 12 Endpoint |
0; 0; 1; 2; 1; 4 | 0.006 sig |
| SECONDARY Erectile Function General Assessment Questionnaire (EF-GAQ) |
135; 155; 74; 126; 146; 67 | <0.001 sig |
| SECONDARY Change From Baseline in Uroflowmetry Parameters - Peak Urine Flow Rate (Qmax) at Week 12 Endpoint |
1.7; 1.6; 1.2 | 0.027 sig |
| SECONDARY Change From Baseline in Uroflowmetry Parameters - Mean Urine Flow Rate (Qmean) at Week 12 Endpoint |
1.0; 0.9; 0.6 | — |
| SECONDARY Change From Baseline in Uroflowmetry Parameters - Voided Volume (Vcomp) at Week 12 Endpoint |
18.5; 13.3; 11.4 | — |
Eligibility Criteria
Inclusion Criteria
- Have BPH Lower Urinary Tract Symptoms (LUTS) based on the disease diagnostic criteria at 1st screening.
- Have a history of ED based on the disease diagnostic criteria at 1st screening.
- Have LUTS with a Total International Prostate Symptom Score (IPSS) greater than or equal to 13 at 2nd screening.
- Have bladder outlet obstruction as defined by a Peak Urine Flow Rate (Qmax) of greater than or equal to 4 to less than or equal to 15 milliliter (mL)/second (sec) (from a prevoid total bladder volume as assessed by ultrasound of greater than or equal to 150 to less than or equal to 550 mL and a minimum voided volume of 125 mL) at 2nd screening.
- Make at least 4 sexual intercourse attempts during the 4-weeks after 2nd screening as recorded in the Sexual Encounter Profile (SEP) diary.
- Are sexually active with an adult female partner, and expect to remain sexually active with the same adult female partner for the duration of the study.
- Agree not to use any other approved or experimental BPH, overactive bladder (OAB), or ED treatments as indicated in the protocol at any time during the study.
- Have not taken treatments indicated in the protocol prior to the 2nd screening.
Exclusion Criteria
- Current treatment with nitrates.
- Prostate-specific antigen (PSA) greater than 10.0 nanogram (ng)/mL at 1st screening.
- PSA greater than or equal to 4.0 to less than or equal to 10.0 ng/mL at 1st screening if prostate malignancy has not been ruled out to the satisfaction of a urologist.
- Clinical evidence of prostate cancer.
- Bladder postvoid residual volume (PVR) greater than or equal to 300 mL by ultrasound determination at 1st screening.
- History or clinical evidence of certain pelvic, bladder, urinary tract, or urinary retention conditions described in the protocol.
- Lower urinary tract instrumentation (including prostate biopsy) within 30 days of 1st screening.
- Clinical evidence of severe hepatic impairment at 1st screening.
- Current neurologic disease or condition associated with neurogenic bladder (for example, Parkinson's disease or multiple sclerosis).
- History of significant renal insufficiency as defined by the protocol.
- History of ED caused by other primary sexual disorders including premature ejaculation or ED caused by untreated endocrine disease.
- Presence of penile deformity judged by the investigator to be clinically significant.
- History of certain cardiac or cardiovascular conditions described in the protocol.
- History of resuscitated cardiac arrest.
- Current treatment with certain medications described in the protocol.
- Scheduled or planned surgery (or any procedure requiring general, spinal, or epidural anesthesia) during the course of the study.
- History of significant central nervous system injuries (including stroke or spinal cord injury) within 6 months of 1st screening.
- Glycosylated hemoglobin (HbA1c) greater than 9% at 1st screening.
- Prior treatment with phosphodiesterase type 5 (PDE5) inhibitors judged by the investigator to be ineffective. However, if the investigator judges that a subject's lack of response to as-needed PDE5 inhibitors is the result of inadequate coordination between dosing and sexual activity with a treatment, the subject may be enrolled.
Data sourced from ClinicalTrials.gov (NCT00855582). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.